These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 23943142)
1. The comparison of 24-hour urinary sodium, albumin, and protein excretion in chronic kidney disease patients with type 2 diabetes mellitus using insulin detemir or insulin glargine. Afsar B Clin Drug Investig; 2013 Oct; 33(10):773-8. PubMed ID: 23943142 [TBL] [Abstract][Full Text] [Related]
2. Effects of insulin detemir and NPH insulin on renal handling of sodium, fluid retention and weight in type 2 diabetic patients. Hendriksen KV; Jensen T; Oturai P; Feldt-Rasmussen B Diabetologia; 2012 Jan; 55(1):46-50. PubMed ID: 22002075 [TBL] [Abstract][Full Text] [Related]
3. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial. Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253 [TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of clinical therapeutic effect of insulin glargine and insulin detemir for patients with type 2 diabetes mellitus. Zhuang YG; Peng H; Huang F Eur Rev Med Pharmacol Sci; 2013 Oct; 17(19):2566-70. PubMed ID: 24142600 [TBL] [Abstract][Full Text] [Related]
6. Detemir vs Glargine: Comparison of Inpatient Glycemic Control. Capson J; Cade K; Avanesyan A J Am Osteopath Assoc; 2019 Feb; 119(2):89-95. PubMed ID: 30688354 [TBL] [Abstract][Full Text] [Related]
7. Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trials. Esposito K; Chiodini P; Capuano A; Petrizzo M; Improta MR; Giugliano D Diabetes Care; 2012 Dec; 35(12):2698-705. PubMed ID: 23173139 [TBL] [Abstract][Full Text] [Related]
8. Weight gain associated with insulin detemir vs insulin glargine in clinical practice: A retrospective longitudinal cohort study. Wadsworth TG; Carr GG; Madaras-Kelly K; Remington R; Bell J Am J Health Syst Pharm; 2021 Feb; 78(5):401-407. PubMed ID: 33354715 [TBL] [Abstract][Full Text] [Related]
9. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus. Porcellati F; Lucidi P; Rossetti P; Candeloro P; Andreoli AM; Marzotti S; Cioli P; Bolli GB; Fanelli CG Diabetes Care; 2011 Dec; 34(12):2521-3. PubMed ID: 21972412 [TBL] [Abstract][Full Text] [Related]
10. Comparing insulins detemir and glargine in type 2 diabetes: more similarities than differences. Commentary. Reynolds LR Postgrad Med; 2010 Jan; 122(1):201-3. PubMed ID: 20107306 [TBL] [Abstract][Full Text] [Related]
11. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine. Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113 [TBL] [Abstract][Full Text] [Related]
12. Insulin detemir: a review of its use in the management of diabetes mellitus. Keating GM Drugs; 2012 Dec; 72(17):2255-87. PubMed ID: 23110609 [TBL] [Abstract][Full Text] [Related]
13. Effect of basal insulin therapy on vascular endothelial function and adipokine profiles in people with Type 2 diabetes. Makino H; Tanaka A; Hosoda H; Koezuka R; Tochiya M; Ohata Y; Tamanaha T; Miyamoto Y; Kangawa K; Kishimoto I Diabet Med; 2016 Dec; 33(12):1737-1743. PubMed ID: 27150701 [TBL] [Abstract][Full Text] [Related]
14. Revisiting the efficacy of long-acting insulin analogues on adults with type 1 diabetes using mixed-treatment comparisons. Sanches AC; Correr CJ; Venson R; Pontarolo R Diabetes Res Clin Pract; 2011 Dec; 94(3):333-9. PubMed ID: 21992870 [TBL] [Abstract][Full Text] [Related]
15. Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis. Pscherer S; Chou E; Dippel FW; Rathmann W; Kostev K Prim Care Diabetes; 2015 Oct; 9(5):377-84. PubMed ID: 25701545 [TBL] [Abstract][Full Text] [Related]
16. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Dejgaard A; Lynggaard H; Råstam J; Krogsgaard Thomsen M Diabetologia; 2009 Dec; 52(12):2507-12. PubMed ID: 19838665 [TBL] [Abstract][Full Text] [Related]
17. Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial. Muskiet MHA; Bunck MC; Heine RJ; Cornér A; Yki-Järvinen H; Eliasson B; Joles JA; Diamant M; Tonneijck L; van Raalte DH Diabetes Res Clin Pract; 2019 Jul; 153():14-22. PubMed ID: 31078666 [TBL] [Abstract][Full Text] [Related]
18. Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine. Pawaskar M; Tuttle KR; Li Q; Best JH; Anderson PW Ann Pharmacother; 2014 May; 48(5):571-6. PubMed ID: 24497624 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of detemir in diabetic cats managed with a protocol for intensive blood glucose control. Roomp K; Rand J J Feline Med Surg; 2012 Aug; 14(8):566-72. PubMed ID: 22553309 [TBL] [Abstract][Full Text] [Related]
20. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]